NCT05419648Completed
Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
Source: ClinicalTrials.gov · Last updated 30 Jul 2025
Brief summary (registry, in English)
Myeloproliferative neoplasms (MPN) are hematological malignancies associated with a major risk of thrombosis. Monocytes are hematopoietic cells with a central role in thrombosis. An activation of monocytes has been demonstrated in MPN patients. However, their study in MPN and their thrombotic complications has never been performed. In this study, we aim to evaluate the association between monocytes sub-populations and thrombotic risk in MPN patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 68 (actual)
- First submitted
- 2 Jun 2022
- Start date
- 5 Oct 2022
- Primary completion date
- 22 Jul 2024
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05419648
What you commit to
- Study type: Observational
- Participants enrolled: 68
- From 5 Oct 2022 to the primary completion date, 22 Jul 2024
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Long term anti-inflammatory treatments:
- Corticoids
- Nonsteroidal anti-inflammatory drugs
- Aspirin (\> 325 mg per day)
- Cyclo-oxygenase II inhibitors
- Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion
Other illness
- Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal diseases).
Other
- Patients with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib) at the time of blood sampling
- Persons under judicial safeguards, trustee or curatorship
- Person unable to give her consent
- Non-cooperative person
Who the study is looking for
- Adults patients (age ≥ 18 years)
- Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional in the presence of a marker of clonality)
- Subject registered with a social security scheme
- Written informed consent obtained
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Bordeaux, Hématologie clinique et thérapie cellulaire Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| CHU de Bordeaux, Médecine Interne et maladies infectieuses Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| CHU de Bordeaux, Laboratoire Hématologie Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| Institut Begonié, Hématologie clinique Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| CHU de Bordeaux, Médecine interne et immunologie clinique Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.